decorative background image

Enzalutamide vs Apalutamide, Darolutamide, and Bicalutamide for Nonmetastatic CRPC

Enzalutamide vs Apalutamide infographic

Tomasz Beer, MD, OHSU Knight Cancer Institute, Oregon Health and Science University, Portland, discusses results from a network meta-analysis comparing the efficacy of enzalutamide vs apalutamide, darolutamide, and bicalutamide for the treatment of nonmetastatic castration-resistance prostate cancer (CRPC).

These results were presented at the virtual 2021 ASCO Genitourinary Cancers Symposium.

Read the full article here. 


Source: Journal of Clinical Pathways

Share